Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives

A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of...

Full description

Bibliographic Details
Authors: Ruíz Villaverde, Ricardo; Vasquez Chinchay, Fiorella; Rodríguez Fernández-Freire, Lourdes; Armario Hita, José Carlos; Pérez Gil, Amalia; Galán Gutiérrez, Manuel
Format: Article
Status:Published version
Publication date:2022
Country:España
Institution:Universidad de Sevilla (US)
Repository:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/146865
Online Access:https://hdl.handle.net/11441/146865
https://doi.org/10.3390/life12091412
Access Level:Open access
Keyword:guselkumab
psoriasis
super-responder
_version_ 1878739506113282048
author Ruíz Villaverde, Ricardo
author2 Vasquez Chinchay, Fiorella
Rodríguez Fernández-Freire, Lourdes
Armario Hita, José Carlos
Pérez Gil, Amalia
Galán Gutiérrez, Manuel
author2_role author
author
author
author
author
author_browse Armario Hita, José Carlos
Galán Gutiérrez, Manuel
Pérez Gil, Amalia
Rodríguez Fernández-Freire, Lourdes
Ruíz Villaverde, Ricardo
Vasquez Chinchay, Fiorella
author_facet Ruíz Villaverde, Ricardo
Vasquez Chinchay, Fiorella
Rodríguez Fernández-Freire, Lourdes
Armario Hita, José Carlos
Pérez Gil, Amalia
Galán Gutiérrez, Manuel
author_role author
collection idUS. Depósito de Investigación de la Universidad de Sevilla
description A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of a multicenter, observational study of real clinical practices including patients with moderate-to-severe plaque PSO undergoing treatment with Guselkumab (GUS). This cross-sectional analysis includes information on patients between February 2019 to February 2022. A SR is a patient that achieved a PASI = 0 at weeks 12 and 24. Analyses have been performed “as observed” using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San Diego, CA, USA, At baseline, the PASI is significantly correlated with VAS_pruritus, BSA, and DLQI, while DLQI is significantly correlated with VAS_pruritus. Significant correlations increase in number and magnitude over the follow-up time. In relation to the univariate logistic models carried out, only three variables showed a significant association with the super-responder variable: depression, VAS_pruritus, and DLQI.SR patients, who show a faster evolution in PASI and BSA improvement than non-SRs. Based on the results obtained, it would be possible to also include DLQI and VAS_pruritus in the broader concept of the SR.
eu_rights_str_mv openAccess
format article
id ES_c2cd3e66eaee214111e2ea425d043bcb
institution Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
network_acronym_str ES
network_name_str España
oai_identifier_str oai:idus.us.es:11441/146865
publishDate 2022
publishDateSort 2022
publisher MDPI
publisherStr MDPI
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
spelling Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives Ruíz Villaverde, Ricardo Vasquez Chinchay, Fiorella Rodríguez Fernández-Freire, Lourdes Armario Hita, José Carlos Pérez Gil, Amalia Galán Gutiérrez, Manuel guselkumab psoriasis super-responder A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of a multicenter, observational study of real clinical practices including patients with moderate-to-severe plaque PSO undergoing treatment with Guselkumab (GUS). This cross-sectional analysis includes information on patients between February 2019 to February 2022. A SR is a patient that achieved a PASI = 0 at weeks 12 and 24. Analyses have been performed “as observed” using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San Diego, CA, USA, At baseline, the PASI is significantly correlated with VAS_pruritus, BSA, and DLQI, while DLQI is significantly correlated with VAS_pruritus. Significant correlations increase in number and magnitude over the follow-up time. In relation to the univariate logistic models carried out, only three variables showed a significant association with the super-responder variable: depression, VAS_pruritus, and DLQI.SR patients, who show a faster evolution in PASI and BSA improvement than non-SRs. Based on the results obtained, it would be possible to also include DLQI and VAS_pruritus in the broader concept of the SR. MDPI https://hdl.handle.net/11441/146865 https://doi.org/10.3390/life12091412
spellingShingle Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
Ruíz Villaverde, Ricardo
guselkumab
psoriasis
super-responder
status_str publishedVersion
title Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_full Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_fullStr Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_full_unstemmed Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_short Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_sort Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
topic guselkumab
psoriasis
super-responder
topic_facet guselkumab
psoriasis
super-responder
url https://hdl.handle.net/11441/146865
https://doi.org/10.3390/life12091412